Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1257)


The recruitment of autologous macrophages to attack osteosarcoma represents a novel immunotherapy approach to the treatment of osteosarcoma. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) was derived as a compound with the ability to stimulate macrophages to destroy autologous osteosarcoma tumor cells. Preclinical studies including studies in dogs with spontaneously arising osteosarcoma showed the ability of L-MTP-PE to control microscopic metastatic disease in osteosarcoma. A pivotal clinical trial led to the approval of L-MTP-PE for the treatment of newly diagnosed osteosarcoma in over 40 countries.


Osteosarcoma Muramyl tripeptide Immunotherapy Macrophages Adjuvant therapy 


  1. 1.
    Coley W (1891) Contribution to the knowledge of sarcoma. Ann Surg 14:199–220CrossRefGoogle Scholar
  2. 2.
    Houghton BB et al (2013) Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int 111(6):977–983CrossRefGoogle Scholar
  3. 3.
    Zwilling BS, Campolito LB (1977) Destruction of tumor cells by BCG-activated alqolar macrophages. J Immunol 119(3):838–841PubMedGoogle Scholar
  4. 4.
    Namba M et al (1978) Antitumor activity of peritoneal exudate cells induced by cell-wall skeleton of Mycobacterium bovis BCG. Gann 69(6):831–834PubMedGoogle Scholar
  5. 5.
    Ellouz F et al (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59(4):1317–1325CrossRefGoogle Scholar
  6. 6.
    Sugimoto M et al (1978) Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP). J Immunol 120(3):980–982PubMedGoogle Scholar
  7. 7.
    Sone S, Poste G, Fidler IJ (1980) Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. J Immunol 124(5):2197–2202PubMedGoogle Scholar
  8. 8.
    Sone S, Fidler IJ (1980) Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol 125(6):2454–2460PubMedGoogle Scholar
  9. 9.
    Fidler IJ et al (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A 78(3):1680–1684CrossRefGoogle Scholar
  10. 10.
    Parant M et al (1979) Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. Int J Immunopharmacol 1(1):35–41CrossRefGoogle Scholar
  11. 11.
    Schroit AJ, Fidler IJ (1982) Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 42(1):161–167PubMedGoogle Scholar
  12. 12.
    Kleinerman ES et al (1983) Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 43(5):2010–2014PubMedGoogle Scholar
  13. 13.
    Murray JL et al (1989) Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 7(12):1915–1925CrossRefGoogle Scholar
  14. 14.
    Kleinerman ES et al (1989) Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49(16):4665–4670PubMedGoogle Scholar
  15. 15.
    Link MP et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314(25):1600–1606CrossRefGoogle Scholar
  16. 16.
    MacEwen EG et al (1989) Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81(12):935–938CrossRefGoogle Scholar
  17. 17.
    Kleinerman ES et al (1995) Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol 17(3):181–193CrossRefGoogle Scholar
  18. 18.
    Kleinerman ES et al (1992) Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother 34(4):211–220CrossRefGoogle Scholar
  19. 19.
    Hudson MM et al (1988) In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res 48(18):5256–5263PubMedGoogle Scholar
  20. 20.
    Asano T et al (1993) Effect of Adriamycin on liposomal muramyl tripeptide’s ability to up-regulate monocyte cytokine expression. Cancer Immunol Immunother 37(6):408–411CrossRefGoogle Scholar
  21. 21.
    Kleinerman ES, Snyder JS, Jaffe N (1991) Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol 9(2):259–267CrossRefGoogle Scholar
  22. 22.
    Miser JS et al (1987) Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5(8):1191–1198CrossRefGoogle Scholar
  23. 23.
    Pratt CB et al (1987) Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 71(2):131–135PubMedGoogle Scholar
  24. 24.
    Meyers PA et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children’s Oncology Group. J Clin Oncol 26(4):633–638CrossRefGoogle Scholar
  25. 25.
    Meyers PA et al (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10(1):5–15CrossRefGoogle Scholar
  26. 26.
    Meyers PA et al (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16(7):2452–2458CrossRefGoogle Scholar
  27. 27.
    Chou AJ et al (2009) Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer 115(22):5339–5348CrossRefGoogle Scholar
  28. 28.
    Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A (2014) Mifarmurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmcokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer 61:238–244CrossRefGoogle Scholar
  29. 29.
    Meyers PA et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23(9):2004–2011CrossRefGoogle Scholar
  30. 30.
    NICE (2011) Mifarmurtide for the treatment of osteosarcoma. Available from:

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Memorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations